Natera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Natera, Inc. (NASDAQ:NTRA) has been given an average rating of “Moderate Buy” by the twenty analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $192.8824.

Several research firms have weighed in on NTRA. Barclays reissued an “overweight” rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Saturday, September 27th. Piper Sandler reissued an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Morgan Stanley restated an “overweight” rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. Finally, Wells Fargo & Company began coverage on Natera in a research report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price target for the company.

Insider Activity

In related news, Director Rowan E. Chapman sold 2,750 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the sale, the director owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00. Following the completion of the transaction, the insider owned 117,559 shares in the company, valued at approximately $18,808,264.41. This trade represents a 2.49% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,464 shares of company stock valued at $10,963,125. 5.63% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. New England Research & Management Inc. grew its position in Natera by 301.6% during the 3rd quarter. New England Research & Management Inc. now owns 6,225 shares of the medical research company’s stock worth $1,002,000 after purchasing an additional 4,675 shares during the period. Roxbury Financial LLC boosted its stake in shares of Natera by 12.5% in the third quarter. Roxbury Financial LLC now owns 900 shares of the medical research company’s stock worth $145,000 after buying an additional 100 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of Natera by 6.6% in the second quarter. Corient Private Wealth LLC now owns 5,796 shares of the medical research company’s stock worth $979,000 after buying an additional 360 shares during the last quarter. Osaic Holdings Inc. grew its holdings in Natera by 49.0% during the second quarter. Osaic Holdings Inc. now owns 9,319 shares of the medical research company’s stock worth $1,562,000 after acquiring an additional 3,065 shares during the period. Finally, American Trust purchased a new position in Natera during the second quarter valued at approximately $226,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $170.38 on Tuesday. Natera has a fifty-two week low of $117.27 and a fifty-two week high of $183.00. The company has a market cap of $23.38 billion, a PE ratio of -89.20 and a beta of 1.74. The business has a 50-day simple moving average of $161.82 and a two-hundred day simple moving average of $156.80.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. Natera’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Natera will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.